Asha Pillai

Sep 1, 2023 | science.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Asha Pillai

Editors' ChoiceFOCIS HIGHLIGHTS Immunotherapy harnessing tumor-infiltrating lymphocytes (TILs) is advancing cures for patients with otherwise-intractable solid tumors. Antibody-targeted endogenous CD8+ T cells and ex vivo engineered autologous chimeric antigen receptor T (CAR-T) or tumor specific antigen (TSA)–specific CD8+ T cells (TCR-T) are potent immunotherapies. However, immune escape when tumors downregulate class I or TSA expression is a key challenge to durable responses.

Sep 1, 2023 | sciencemag.org | Jonna Alanko |Xin Lan |Hannah Donnelly |Asha Pillai

Editors' ChoiceFOCIS HIGHLIGHTSImmunotherapy harnessing tumor-infiltrating lymphocytes (TILs) is advancing cures for patients with otherwise-intractable solid tumors. Antibody-targeted endogenous CD8+ T cells and ex vivo engineered autologous chimeric antigen receptor T (CAR-T) or tumor specific antigen (TSA)–specific CD8+ T cells (TCR-T) are potent immunotherapies. However, immune escape when tumors downregulate class I or TSA expression is a key challenge to durable responses.